Can Black Swan Graphene escape the lab and win in manufacturing with this Québec acquisition?
Black Swan Graphene Inc. is acquiring Falpaco in a C$12.6M deal. Discover how this move could accelerate graphene commercialization and industrial growth.
Tesoro Minerals Corp. strengthens exploration pipeline with Peru epithermal projects deal (TSXV: TES)
Tesoro Minerals Corp acquires Peru gold projects. Find out how this move could shape its exploration strategy and investor outlook.
Can Banzai International escape small-cap software limbo with its ConnectAndSell move? (NASDAQ: BNZI)
Find out how Banzai International’s ConnectAndSell deal could double revenue and test its AI software strategy in 2026. Read more.
Can Unusual Machines, Inc. turn fresh equity capital into a durable lead in domestic drone parts manufacturing? (NYSE American: UMAC)
Unusual Machines raises $150M to expand drone parts supply. Discover how this move could reshape U.S. manufacturing and investor sentiment.
Rocket Lab Corporation extends Synspective momentum as constellation demand lifts launch visibility (NASDAQ: RKLB)
Rocket Lab Corporation launched Synspective’s eighth StriX satellite. Read how the mission could deepen its edge in commercial and defense space markets.
What ParaZero Technologies Ltd.’s latest India demo could signal for its global counter-drone ambitions (NASDAQ: PRZO)
ParaZero Technologies Ltd. expands into India with BonV Aero. Find out how this counter-drone move could shape its global ambitions.
Dry bulk deal drama deepens as Diana Shipping turns up heat on Genco after bid rejection (NYSE: DSX, NYSE: GNK)
Diana Shipping is escalating its bid for Genco after a board rejection. Read what the clash means for dry bulk valuations, M&A, and investors.
Why CNS drug developers are paying attention to Alamar Biosciences’ latest move
How Alamar Biosciences’ Neuro 220 Panel could reshape CNS biomarker discovery and drug trials. Explore the strategic implications now.
What AACR 2026 could reveal about Immunocore Holdings plc’s long-term immunotherapy durability (NASDAQ: IMCR)
Can Immunocore’s five-year KIMMTRAK data reshape oncology expectations? Discover the strategic, clinical, and investor implications now.
FDA approval positions MyChoice CDx as key HRD test for ovarian cancer therapy selection
Myriad Genetics secures FDA approval for MyChoice CDx with Zejula. Discover how this reshapes oncology diagnostics and precision medicine markets.